New Products | GenomeWeb

New Products

Jan 11, 2017

Celmatix Fertilome

Celmatix has launched Fertilome, a genetic screen that reveals how a woman's DNA may influence her reproductive health. The test analyzes a patient's blood samples for genetic factors associated with the most common reproductive conditions that can lead to fertility difficulties in women, including endometriosis, polycystic ovarian syndrome, and primary ovarian insufficiency. Fertilome is available through physicians.

Jan 11, 2017

Dolomite Bio Injection Valve and Sample Loop

Dolomite Bio has launched a Injection Valve and Sample Loop for single cell RNA sequencing workflows. The product is a complete four-way valve module which allow barcoded mRNA capture beads in lysis buffer to efficiently flow through the RNA-Seq chip. Its design and simple microfluidic connections enable seamless switching between the injection of the bead suspension and pumping of a driving fluid. This produces minimal dead volume and bead wastage compared to traditional syringe pump methods, the company said.

Jan 11, 2017

Bioline EPIK MiRNA Select Assays

Meridian Bioscience subsidiary Bioline has launched a full range of EPIK miRNA Select assays. The recent release includes all of the organisms listed on the miRBase release 21, which increases the number of EPIK miRNA assays to over 27,000. Each assay was designed in collaboration with MiRXES in silico using thermodynamics-based algorithms. They also include miRNA specific reverse transcriptase primers and hemi-nested real-time PCR primers along with Bioline reverse transcriptase, SensiSmart with SYBR Green, and optimized buffers.

Jan 09, 2017

Cynvenio ClearID Breast Cancer Test

Cynvenio Biosystems released its updated ClearID Breast Cancer blood test, which leverages a custom-developed NGS panel of 27 genes known to be altered in breast cancer. The updated test identifies circulating tumor cell burden and detects emerging genetic alterations that are associated with therapy resistance. The assay has been optimized to monitor patients with advanced breast cancer during the start of therapy and at regular intervals following treatment. 

Jan 09, 2017

Pacific Biosciences Sequel Chemistry and Software Update

Pacific Biosciences has launched a new chemistry, V2, and new software, V4, for its Sequel sequencing system that will be available on Jan. 23. The release also includes a new version of the consumable SMRT cells. The updates improve the system's ability to support applications such as structural variant detection and targeted sequencing for tasks such as metagenomics, minor variant detection, and isoform sequencing. The mean read length is now 10 to 18 kilobases, with half the data in reads larger than 20 kilobases. Throughput is now 5 to 8 gigabases, depending on sample type and sample prep method used. The system is now also capable of loading 80-kilobase sequencing libraries. The new software includes updates to the base-calling algorithm that increase accuracy and new features to the system software to support clinical research applications.

Jan 05, 2017

Core Informatics Sanger Sequencing and Microarray Genotyping Apps

Core Informatics has released two applications for its Platform for Science that are designed to help researchers execute microarray genotyping and Sanger sequencing workflows. The company's Sanger sequencing application provides data management tools for small-scale projects in both regulated and non-regulated laboratory environments. It includes capabilities for analyzing long reads as well as for validating next-generation sequencing results. The microarray genotyping application lets users track samples as well as capture and manage data as part of large-scale genotyping projects.

Jan 05, 2017

Baylor Genetics PreSeek for Prenatal Multi-Gene Sequencing Screen

Baylor Genetics has launched PreSeek, a clinical non-invasive prenatal multi-gene sequencing screen. The test requires blood and/or saliva samples from each parent, then sequences cell-free fetal DNA for de novo disease-causing variants associated with select single-gene conditions affecting the skeletal, cardiac, and neurological systems. It is complementary to traditional prenatal screening tests, the company said.

Jan 03, 2017

Fluidigm C1 Medium-Cell High-Throughput IFC

Fluidigm has released its new high-throughput integrated fluidic circuit (HT IFC) for isolating medium-sized single cells using the firm's C1 system for mRNA sequencing. The device captures up to 800 single cells, between 10 and 17 micrometers, at higher capture efficiency and comes with live, on-IFC imaging for viability and phenotypic analysis. The firm added that the new chip enables scaling of cell atlas and lineage study applications.

Dec 28, 2016

Zymo Research Sample Collection Devices

Zymo Research has launched five new sample collection devices featuring the company's DNA/RNA Shield storage reagent, which preserves the integrity and expression profiles of samples including cells, tissues, blood, plasma, serum, saliva, urine, and feces at ambient temperatures for extended periods.

The new collection devices are: DNA/RNA Shield Swab Collection Tube, ideal for mouth, nose, throat, and environmental samples; DNA/RNA Shield Blood Collection Tube, ideal for gene expression analysis, miRNA analysis, and blood-borne pathogen detection; DNA/RNA Shield Fecal Collection Tube, which can be used for miRNA analysis, pathogen detection, gene expression, and microbiomic analysis; and DNA/RNA Shield Lysis Tubes for tissues and microbes.

Dec 22, 2016

GenBank 217

GenBank 217 is now available via ftp from the National Center for Biotechnology Information. Uncompressed flatfiles in this release require 809 gigabytes for sequence files only. The ASN.1 data requires approximately 671 GB.

Dec 21, 2016

Invitae Pediatric, Neurological, and Rare Disease Test Expansion

Invitae has launched 42 new and 19 expanded genetic test panels as part of the company's pediatric, neurological, and rare disease offerings. The new offerings allow clinicians to gain information on 183 genes with clinical and diagnostic significance. The expanded offerings include comprehensive testing for epilepsy and epilepsy-related disorders; an expansion of panel testing for developmental disorders, overgrowth syndromes, skeletal disorders, and RASopathies/Noonan spectrum disorders; incorporation of the latest genetic findings for ciliopathies; and consolidation of clinical areas, enabling customers to order a broader set of tests that are relevant for the patient.

Dec 21, 2016

Fluidigm Medium-Cell HT IFC

Fluidigm has launched its medium cell, high-throughput integrated fluidic circuit to isolate single cells for mRNA sequencing analysis. The circuit captures up to 800 medium-size cells with higher single-cell capture efficiency, which enables researchers to scale cell lineage studies using Fluidigm's C1 system, the company said. The new workflow supports the identification of cell subpopulations present at low abundance across a wide range of cell types, including cancer and stem cells.

Dec 21, 2016

Natera Constellation Update

Natera has launched an update to Constellation, its cloud-based software platform. The update includes the addition of microdeletion testing capability, which allows researchers to test for chromosomal abnormalities in the fetus. This testing includes the company's Panorama prenatal test which can screen for a number of chromosomal abnormalities in a developing fetus, including 22q11.2 deletion syndrome.

Dec 21, 2016

Cellecta Single-Module CRISPR Human Genome-Wide 80K Knockout Library

Cellecta has launched the single-module CRISPR Human Genome-Wide 80K Knockout library. The new library includes 4 guide RNAs per gene and is half the size of the company's current three-module CRISPR 150K Human Genome-Wide Knockout Library. The reduced library size enables researcher to study how cells respond to the disruption of each gene across the entire human genome in a single screening experiment. This aids the researchers ability to identify genetic elements that are functionally important in biological responses and identify new therapeutic targets.

Dec 21, 2016

PGDx CancerSELECT 125 Test

Personal Genome Diagnostics has launched the CancerSELECT 125 test for pan-cancer tumor profiling. The test identifies clinically actionable and functionally important sequence mutations, and structural alterations across multiple cancer types using the company's proprietary technologies and bioinformatics. The test also reports microsatellite instability status to assess potential response to checkpoint inhibitor therapies. Additionally, it includes matched sequencing of normal patient tissue to accurately filter out germline variants.

Dec 21, 2016

Pacific Edge Cxbladder Monitor

Pacific Edge has launched the Cxbladder Monitor, a urine-based gene expression test for investigation of bladder cancer in patients being monitored for recurrent disease. The test analyzes urine samples for expression genes, clinical, and patient variable factors that create unique molecular signatures for urothelial carcinoma. It is designed to be used on patients undergoing bladder cancer surveillance to determine if they have a low probability of having recurrence.

Dec 21, 2016

Clinical Genomics Colvera

Clinical Genomics has launched Colvera, a blood-based test for colorectal cancer recurrence monitoring. The test measures methylation in circulating tumor DNA and can indicate the presence or absence of two altered genes associated with colorectal cancer. Colvera only requires a peripheral blood sample and can be administered alongside other colorectal cancer surveillance tests, the company said.

Dec 19, 2016

Aeon Clinical Laboratories MDx Advantage Women's Health Test

Aeon Clinical Laboratories, a wholly-owned subsidiary of Authentidate Holding Corp, has launched MDx Advantage, a qPCR-based diagnostic test for STDs and other infections, from its labs in Gainesville, Georgia. Aeon's test targets 34 common causes of vaginal infections, including bacteria, fungi, viruses, and protozoa.

Dec 15, 2016

Oxford Gene Technology Cytocell Aquarius FISH Probes for Sarcoma

Oxford Gene Technology has launched three new Cytocell Aquarius FISH probes for pathology. The FUS Breakapart and FOXO1 Breakapart probes are CE-IVD marked. The TFE3 Breakapart probe is for research-use only, the company said. 

Dec 15, 2016

Desktop Genetics Site-Seq Service

Desktop Genetics has launched Site-Seq, a next-generation sequencing and analysis service. The service uses targeted deep amplicon sequencing to detect CRISPR editing events at frequencies as low as 0.1 percent.

Dec 15, 2016

PHEMI Central Precision Medicine Edition

PHEMI has launched the Central Precision Medicine Edition, an out-of-the-box solution leveraging Oracle Big Data appliance and built upon Hadoop Big Data technology for affordable scalability and fast query capabilities. It allows researchers to ingest, index, annotate, and search large amounts of genomic data and achieve sub-second query performance. The solution uses standard interfaces, such as the Global Alliance for Genomics and Health API, to provide integration with existing analytics tools, while PHEMI's built-in data management and privacy functionality enforce researcher's rightful access to data.

Dec 14, 2016

Med Fusion HemeSEQ Profiles

Med Fusion has launched an expansion of its oncology testing services to include HemeSEQ portfolio of next-generation sequencing profiles. The profiles cover four hematologic neoplasms: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, and Myeloproliferative Neoplasms. These profiles expand the company's hematologic testing menu to nearly 100 tests and incorporate next-generation sequencing technology. Customer tests results are matched with relevant clinical trials and therapy options based on the specific genomic signature of the patient's disease, the company said. The final report is easy to read and delivers oncologists a powerful tool to access diagnosis and prognosis of patients living with hematologic disease.

Dec 14, 2016

PreventionGenetics Comprehensive Miscarriage, Stillbirth, and Neonatal Death Panel

PreventionGenetics has launched the Comprehensive Miscarriage, Stillbirth, and Neonatal Death panel. The panel includes chromosomal microarray (CMA-ISCA) followed by a 40-gene next-generation sequencing panel in cases with a normal microarray result, or a 40-gene panel of single-gene disorders in cases with negative CMA results. If CMA has already been performed, the company said it offers the NGS panel individually.

Dec 13, 2016

Protagen NavigAid SSc

Progtagen has launched the NavigAid systemic sclerosis (SSc) disease stratification assay for use in drug development.

NavigAid SSc achieves patient stratification by measuring serum biomarkers and has been specifically developed to address heterogeneity in patients with the disease. The assay enables differential diagnosis, risk stratification, and prediction of organ involvement.

Dec 13, 2016

KbioBox Bioinformatics Portal

KBioBox has released the KbioBox bioinformatics portal that includes a “3 click” gene editing off target analysis program and a “3 Click” gene edit biodesign program. The gene edit off target analysis solution identifies off targets in whole genomes while the gene edit design analysis solution provides top ten biodesigns based on input information. Both solutions return simple annotated reports that include intuitive visualizations, locus information, and whole-genome off target analysis for designs.

Pages

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.